Insider Selling: AngioDynamics, Inc. (ANGO) CFO Sells $41,746.67 in Stock

AngioDynamics, Inc. (NASDAQ:ANGO) CFO Michael Greiner sold 1,939 shares of the firm’s stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $21.53, for a total transaction of $41,746.67. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Shares of NASDAQ ANGO opened at $21.38 on Friday. AngioDynamics, Inc. has a 52-week low of $15.16 and a 52-week high of $24.49. The stock has a market capitalization of $812.59 million, a PE ratio of 28.43 and a beta of 0.75. The company has a current ratio of 2.64, a quick ratio of 1.55 and a debt-to-equity ratio of 0.16.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Thursday, September 27th. The medical instruments supplier reported $0.16 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.18 by ($0.02). AngioDynamics had a net margin of 4.62% and a return on equity of 5.44%. The company had revenue of $85.34 million during the quarter, compared to analyst estimates of $84.05 million. During the same quarter last year, the business earned $0.13 EPS. The firm’s revenue for the quarter was down .1% compared to the same quarter last year. Research analysts predict that AngioDynamics, Inc. will post 0.85 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in ANGO. BlackRock Inc. grew its holdings in shares of AngioDynamics by 5.1% in the third quarter. BlackRock Inc. now owns 5,759,289 shares of the medical instruments supplier’s stock valued at $125,206,000 after purchasing an additional 280,501 shares in the last quarter. Thomson Horstmann & Bryant Inc. grew its holdings in shares of AngioDynamics by 10.5% in the third quarter. Thomson Horstmann & Bryant Inc. now owns 389,511 shares of the medical instruments supplier’s stock valued at $8,467,000 after purchasing an additional 37,114 shares in the last quarter. Heartland Advisors Inc. grew its holdings in shares of AngioDynamics by 41.0% in the third quarter. Heartland Advisors Inc. now owns 503,827 shares of the medical instruments supplier’s stock valued at $10,953,000 after purchasing an additional 146,498 shares in the last quarter. Keybank National Association OH acquired a new position in shares of AngioDynamics in the third quarter valued at approximately $409,000. Finally, First National Bank of Omaha grew its holdings in shares of AngioDynamics by 17.9% in the third quarter. First National Bank of Omaha now owns 41,062 shares of the medical instruments supplier’s stock valued at $893,000 after purchasing an additional 6,227 shares in the last quarter. Institutional investors and hedge funds own 97.54% of the company’s stock.

Several analysts recently commented on ANGO shares. BidaskClub lowered shares of AngioDynamics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, August 1st. Zacks Investment Research upgraded shares of AngioDynamics from a “sell” rating to a “hold” rating in a research report on Tuesday, September 11th. Four equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $18.44.

TRADEMARK VIOLATION NOTICE: “Insider Selling: AngioDynamics, Inc. (ANGO) CFO Sells $41,746.67 in Stock” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/11/11/insider-selling-angiodynamics-inc-ango-cfo-sells-41746-67-in-stock.html.

About AngioDynamics

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

See Also: Outstanding Shares

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply